Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,815 across all filing types
Latest filing 2025-04-14 Transaction in Own Shar…
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Transaction in Own Shares 2025
Transaction in Own Shares Classification · 1% confidence The document is titled "Transactions in Connection with Share Buy-back Program" and explicitly details the number of shares repurchased daily under a previously announced share buy-back program. This activity directly relates to the company managing its own stock, which falls under the definition of 'Transaction in Own Shares'. The document is a formal company announcement detailing these transactions, not just a general regulatory filing or a report announcement.
2025-04-14 English
Transaction in Own Shares 2025
Transaction in Own Shares Classification · 1% confidence The document is titled "Transactions in Connection with Share Buy-back Program" and provides detailed tables showing the number of shares repurchased daily by the company (Genmab A/S) under an announced program. This activity directly relates to the company managing its own stock, which falls under the definition of 'Transaction in Own Shares'. The filing explicitly details the execution of share repurchases, matching the description for code POS.
2025-04-14 English
Director's Dealing 2025
Director's Dealing Classification · 1% confidence The document text consists almost entirely of tables detailing transactions for 'GENMAB A/S' on '07-Apr-2025', showing Quantity, Price (DKK), and Venue. This structure is characteristic of regulatory filings reporting insider transactions or director dealings. Comparing this content to the provided definitions, the category 'Director's Dealing (Code: DIRS)' is the most appropriate fit, as it covers 'Report of personal share transactions by company directors and executives (insider trades)'. The document is not a general financial report (10-K, IR, ER) or a general announcement (RPA, RNS), but a specific report of share transactions.
2025-04-14 English
6-K
Foreign Filer Report
2025-04-10 English
6-K
Foreign Filer Report
2025-04-10 English
Share Issue/Capital Change 2025
Share Issue/Capital Change Classification · 1% confidence The document is titled 'Genmab A/S Share Capital Reduction' and is issued as a 'Company Announcement'. The content explicitly states that the share capital reduction, decided at the AGM, has been registered with the Danish Business Authority, detailing the resulting number of shares. This action—a change in the company's capital structure following a shareholder vote—most closely aligns with the 'Share Issue/Capital Change' category (SHA). Although it relates to a decision made at the AGM, the core subject is the capital structure change itself, not the AGM materials (AGM-R) or the voting results (DVA). Since it involves a reduction/cancellation of shares, SHA is the most precise fit.
2025-04-10 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.